Search - tctmd.com

Displaying 101 - 120 of 167

Sort: Relevancy | Date

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Shelley Wood

May 28, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Michael O'Riordan

February 25, 2019

News Daily News

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Michael O'Riordan

January 11, 2019

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

Todd Neale

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

Advertisement

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Top News in Coronary Artery Disease: 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content